

In collaboration with The Oxford University Clinical Research Unit, Vietnam



MONDAY 04 NOVEMBER 2024

Venue: Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

Time	Activity
14.00	Option of tours to be arranged of the laboratories at the Oxford University Clinical Research Unit

These tours will be limited due to capacity issues and delegates will be notified accordingly in due course.

The programme is subject to change



5th ANNUAL NETWORK MEETING

TUESDAY 05 NOVEMBER 2024

Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam

Time	Activity
08.30	<i>Registration</i>
09.00	Welcome - Network Information <i>Professor Cal MacLennan, Director of BactiVac & Professor Adam Cunningham, Co-Director of BactiVac, UK</i>
09.15	BactiVac Network - Opening Address <i>Professor Peter Borriello, Trustee of Safe Medicines for Animals - regulatory training (SMart), UK</i>
09.30	Oxford University Clinical Research Unit - Opening Address <i>Professor Guy Thwaites, Director, Oxford University Clinical Research Unit, Vietnam</i>
09.45	EDV01: A Quadrivalent <i>Shigella</i> Conjugate Vaccine <i>Dr Aurelio Bonavia, Vaccine Discovery Project Leader, Bill & Melinda Gates Medical Research Institute USA</i>
10.15	Development and Qualification of Immunoassays for <i>Shigella</i> Vaccines <i>Mr Paul Rhyne, Bioassay Lead, Gates Medical Research Institute, USA</i>
10.45	Speed Networking Session
12.30	<i>Lunch</i>
13.30	Technologies Available for Bacterial Vaccines <i>Dr Francesca Micoli, Senior Project Leader and Director of the Innovation Academy at GSK Vaccine Institute for Global Health</i>
14.00	MRNA as a Platform for Bacterial Vaccines <i>Dr Obadiah Plante, Sr. Director, Bacteriology, Infectious Disease Research, Moderna, USA</i>
14.30	Combination Bacterial Vaccines <i>Professor Dr Annelies Wilder-Smith, WHO Team Lead Vaccine Development, Switzerland</i>
15.00	<i>Refreshments</i>
15.30	Vaccine Clinical Trials, Recent Advancements, Challenges & Opportunities <i>Dr Tarun Saluja, Head of Clinical Development, International Vaccine Institute, South Korea</i>
16.00	Oral Paratyphoid Vaccine Study in the Human Challenge Model <i>Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the University of Oxford and a Consultant Paediatrician at the Oxford Children's Hospital, UK</i>
16.30	Klebsiella Pneumoniae in Vietnam: The Urgent Need for a Vaccine <i>Dr Duy Pham, Head of Molecular Epidemiology Group, Oxford University Clinical Research Unit, Vietnam</i>
17.00	Bangladesh Vaccine Therapeutics Diagnostics and Manufacturing and Regulatory Strengthening <i>Dr Dinesh Arora, Principal Health Specialist, Asian Development Bank, Philippines</i>
17.30	<i>Close of day programme</i>
19.00	Conference Dinner – The Sheraton Hotel

Page 2 of 5



5th ANNUAL NETWORK MEETING

WEDNESDAY 06 NOVEMBER 2024

Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam

Time	Activity
09.00	DCVMN in Pursuit for Excellence: A Journey of Innovations, Development, Manufacturing and Delivery of Bacterial Vaccines <i>Mr Rajinder Kumar Suri, CEO, DCVMN International, India</i>
09.30	Biological E's Longstanding Commitment of Bacterial Vaccine Development <i>Dr Nupur Sengupta, General Manager, Global Alliance Management, Bio E-Vaccines, India</i>
10.00	The Group B Streptococcal Vaccine Pipeline <i>Professor Kirsty Le Doare, Professor of Vaccinology and Immunology, St. George's. University of London, UK</i>
10.30	Group B Streptococcal Vaccine <i>Speaker TBC</i>
11.00	<i>Refreshments</i>
11.30	Encouraging the Use of Biological Products and Vaccines to Replace Antibiotics to Meet the Export Strategy of the Ministry of Agriculture and Rural Development <i>Dr Dang Thi Thanh SON, Head of Veterinary Hygiene Department, National Institute for Veterinary Research (NIVR), Vietnam</i>
12.00	Reduction of Antibiotic Use in Tilapia Farming <i>Associate Professor Nguyen Ngoc Phuoc, Senior Lecturer, Faculty of Fishery, University of Agriculture and Forestry, Hue University, Vietnam</i>
12.30	Streptococcus suis Infection in Human: A New Insight from Whole Genome Sequence Study <i>Associate Professor Ngo Thi Hoa, Head of Zoonoses Group, Oxford University Clinical Research Unit, Vietnam</i>
13.00	<i>Lunch</i>
14.00	BactiVac Network Opportunities <i>Dr Jo Dean, Operations Manager, BactiVac Network, UK</i>
14.30	Oral Presentations from Selected Poster Abstracts See Appendix 1
16.00	Poster Abstract Viewing
18.00	<i>Close of day programme</i>

The programme is subject to change



Page 3 of 5



5th ANNUAL NETWORK MEETING

THURSDAY 07 NOVEMBER 2024 Venue – Sheraton Hotel, Ho Chi Minh City, Vietnam

Time	Activity
09.00	The Challenge of Developing Vaccines against Human Adapted Pathogens <i>Professor Christoph Tang, Professor of Cellular Pathology, Sir William Dunn School of Pathology, UK</i>
09.30	Clinical Trials in Asia – Opportunities and Challenges <i>Dr Evelyne Kestelyn, Head of the Clinical Trials Unit, Oxford University Clinical Research Unit, Vietnam</i>
10.00	The Role of the Social Structure in Vaccine Hesitancy <i>Dr Ha Nguyen Thanh, Postdoctoral Researcher, Oxford University Clinical Research Unit, Vietnam</i>
10.30	<i>Refreshments</i>
11.00	The Clinical Challenge of <i>Acinetobacter baumannii</i> and Potential New Therapeutic Approaches <i>Professor Jeremy Brown, Professor of Respiratory Infection, University College London, UK</i>
11.30	K-Vax: The Universal Vaccine for Prevention of Diseases by <i>Klebsiella Pneumoniae</i> <i>Dr Aida Alonso-del Valle, Vaccine Development Manager, Vaxdyn, Spain</i>
12.00	Perspective on the Success of Bacterial Vaccine Development and Manufacture in Asia <i>Dr Jerome Kim, Director General of the International Vaccine Institute, South Korea</i>
12.30	<i>Lunch</i>
14.00	Translational Workshop by Hilleman Laboratories What Does it Take to Move a Vaccine Through the First ‘Valley of Death?’ Welcome & Opening <i>Dr Alain Bouckenoghe, Head of Research & Development, Hilleman Laboratories, Singapore</i>
14.05	Complexities of Vaccine Development <ul style="list-style-type: none">➤ From scientific challenges to safety & efficacy and preclinical research➤ Challenges in clinical trials, regulatory hurdles, scale-up manufacturing
14.30	Building a Business Case
15.00	Case Study
15.30	<i>Refreshments</i>
16.00	Panel Session Q&A Session
17.00	Annual Network Meeting Closing Address <i>Professor Cal MacLennan, Director of BactiVac & Professor Adam Cunningham, Co-Director of BactiVac, UK</i>

The programme is subject to change



WEDNESDAY 06 NOVEMBER 2024

Oral Presentations from Selected Poster Abstracts

- 14.30 **Turbo: an adjuvant for bacterial polysaccharide vaccines**
Dr Kishore R. Alugupalli, Chief Executive Officer, TurboVax Inc., USA
- 14.45 **Safety and immunogenicity of a 4-component GMMA-based *Shigella* vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial**
Dr Ashwani Kumar Arora, Head Clinical Development & Regulatory Affairs, GSK Vaccines for Global Health, Italy
- 15.00 **Exploring the role of pneumococcal conjugate vaccine (PCV)-13 and its mechanism against *Streptococcus pneumoniae***
Dr Gift Chiwala, Postdoctoral Research Associate, Malawi Liverpool Wellcome Programme, Malawi
- 15.15 **Comparative analysis of gonococcal antibody levels and function in sera from mice immunised with candidate native Outer Membrane Vesicle (nOMV) gonococcal vaccines and from patients convalescing from gonorrhoea**
Ms Ilaria Onofrio, DPhil student, Jenner Institute, University of Oxford, UK
- 15.30 **Live vector-based multivalent vaccine approach against cecal colonization of *Campylobacter jejuni* in commercial chickens**
Dr Amirul Islam Mallick, Associate Professor, Indian Institute of Science Education and Research Kolkata, India
- 15.45 **Preliminary analysis and outcomes from a first-in-human Nontyphoidal *Salmonella* controlled human infection model**
Dr Christopher Smith, Clinical Research Fellow, Imperial College London, UK

The programme is subject to change

